CLPS Inc current report, Q2 FY2018

CLPS Inc. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K was filed by CLPS Inc. on June 11, 2018, covering events occurring in June 2018. The Company is a foreign private issuer reporting under Form 20-F. Its shares trade on The Nasdaq Capital Market under the symbol "CLPS."

Key Financial Metrics

The filing details the financial impact of the Company's Initial Public Offering (IPO) and the subsequent exercise of the over-allotment option:

  • Over-Allotment Exercise: On June 8, 2018, the underwriters exercised the option to purchase an additional 300,000 common shares.
  • Price per Share: $5.25.
  • Gross Proceeds from Over-Allotment: Approximately $1.58 million.
  • Total IPO Gross Proceeds: Approximately $12.08 million (combining the initial $10.5 million and the $1.58 million from the over-allotment).
  • Net Proceeds: The filing states gross proceeds are before underwriting discounts, commissions, and offering expenses; net proceeds are not specified.

The filing does not provide data on revenue, profit, cash flow, operating margins, debt levels, or liquidity ratios for the reporting period.

Material Changes

The primary material change reported is the full exercise of the over-allotment option, increasing the total capital raised in the IPO. Additionally, the Company and the underwriter, The Benchmark Company, LLC, entered into an agreement on June 8, 2018, to terminate the right of first refusal provision (Section 7.2) of the Underwriting Agreement dated May 23, 2018.

Guidance, Outlook, and Risks

The filing contains no management commentary regarding future guidance, outlook, or specific risk factors. It is a procedural report confirming the closing of the over-allotment and the termination of a specific contractual provision.

Investor Verification Checklist

  • Verify the final net proceeds after deducting underwriting discounts and offering expenses.
  • Confirm the total number of shares outstanding following the issuance of the 300,000 additional shares.
  • Review the terminated right of first refusal provision to understand its prior implications on future capital raises.
  • Check subsequent filings for the use of proceeds from the $12.08 million gross capital raise.